SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Preventive Visit — Wilma Rudolph

PatientWilma Rudolph
Date of birth1972-06-23
IdentifiersMRN HR-ML036-SYN; SSN (made up) 000-36-5170
Document date2026-10-29
AuthorGloria Haynes-Whitaker, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Ms. Rudolph is a 54-year-old hospital executive and former Olympic sprinter with an IDH-wildtype, MGMT-methylated glioblastoma of the left frontal lobe, treated with gross total resection and six weeks of radiotherapy with daily temozolomide, who comes for her yearly preventive visit on day 21 of her first adjuvant temozolomide cycle. The MRI three weeks ago showed no progression. She took the five doses of temozolomide without vomiting, using ondansetron before each. She wears the tumor-treating fields device about 19 hours a day; the scalp under the arrays is a little pink but not broken. She is tired by mid-afternoon but works mornings from home. She has had no headache, seizure, change in speech, weakness or fall. Her right hand is back to normal for writing. She walks most days with the cane she keeps for uneven ground. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 54
GlioblastomaNo progression on the post-chemoradiation MRI; adjuvant cycle 1, day 21
Tumor-treating fieldsAbout 19 hours a day; mild scalp redness
MoodPHQ-2 1

Health risk assessment. Completed by the patient on the clinic's paper form in the waiting room and reviewed with her by Dr. Haynes-Whitaker. [S]

DomainFinding
Self-rated healthFair; tired in the afternoons
PsychosocialClose to her family and friends; still working part days; keeps her spirits up with time with her family and her foundation's young athletes
Substance useNo tobacco; no alcohol since surgery; no drug use
Physical activityWalks 20 to 30 minutes most days; home exercises from physical therapy three times a week
NutritionAppetite fair; eats small meals; weight steady
SleepSeven to eight hours with the device on; a short nap after lunch
Falls and home safetyNo falls; grab bars and night lights in place; cane for uneven ground
DrivingNot driving since the first symptoms; family and friends drive her
Activities of daily livingIndependent in all
Seat belt and smoke alarmsAlways wears a seat belt; smoke alarms tested

Review of Systems

SystemResultFinding
ConstitutionalPositiveAfternoon fatigue; no fever or weight loss
EyesNegativeNo double or blurred vision
Ears, nose, mouth, and throatNegativeNo mouth sores or sore throat
CardiovascularNegativeNo chest pain or leg swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeNo nausea now, vomiting, diarrhea or constipation
GenitourinaryNegativeNo urinary symptoms; no vaginal bleeding
BreastNegativeNo lump or nipple change
MusculoskeletalNegativeNo new weakness, muscle pain or joint pain in either leg
IntegumentaryPositiveMild pinkness of the scalp under the device arrays; no blisters or broken skin
NeurologicalNegativeNo headache, seizure, numbness or speech change
Hematologic and lymphaticNegativeNo bruising or bleeding
PsychiatricNegativeMood steady; PHQ-2 1

13 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-06-29activeS
Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgeryOne tablet twice a day with breakfast and lunchOral route2026-06-30 to 2026-07-08completedS
Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasoneOne tablet twice a dayOral route2026-06-30 to 2026-08-12completedS
Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, taperingOne tablet twice a dayOral route2026-07-10 to 2026-07-29completedS
Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stopOne tablet daily for a week, then half a tablet daily for a weekOral route2026-07-29 to 2026-08-12completedS
Temozolomide 140 mg oral capsule, 140 mg (75 mg/m2) by mouth daily at bedtime on an empty stomach, seven days a week for 42 days from the first day of radiotherapyOnce daily at bedtime, seven days a week, for 42 daysOral route2026-08-03 to 2026-09-13completedS
Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumoniaOne tablet on Monday, Wednesday and FridayOral route2026-08-03activeS
Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nauseaBefore each temozolomide dose; every 8 hours as neededOral route2026-08-03activeS
Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6Two capsules once daily at bedtime on days 1 to 5 of each 28-day cycleOral route2026-10-09activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-29Body height180cmS
2026-10-29Body weight66.9kgS
2026-10-29Body mass index (BMI) [Ratio]20.6kg/m2S
2026-10-29Systolic blood pressure118mm[Hg]S
2026-10-29Diastolic blood pressure72mm[Hg]S
2026-10-29Heart rate76/minS
2026-10-29Respiratory rate14/minS
2026-10-29Body temperature36.5CelS
2026-10-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-29Hemoglobin [Mass/volume] in Blood11.8g/dL12-15.5 g/dLLowS
2026-10-29Leukocytes [#/volume] in Blood by Automated count3.410*3/uL4-11 10*3/uLLowS
2026-10-29Neutrophils [#/volume] in Blood by Automated count1.910*3/uL1.5-7.7 10*3/uLNormalS
2026-10-29Lymphocytes [#/volume] in Blood by Automated count0.610*3/uL1-4 10*3/uLLowS
2026-10-29Platelets [#/volume] in Blood by Automated count12110*3/uL150-400 10*3/uLLowS
2026-10-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma33U/L7-35 U/LNormalS
2026-10-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L8-35 U/LNormalS
2026-10-29Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 2026-10-29; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 66.9 kg; blood pressure 118/72; pulse 76; temperature 36.5 °C
HeadCraniotomy incision healed; hair loss over the radiation field; scalp under the arrays mildly pink, intact
MouthNo ulcers or thrush
BreastsClinical breast examination with a chaperone, at her choice: no masses, skin or nipple changes, or axillary nodes
CardiovascularRegular rhythm; no murmur
RespiratoryClear
AbdomenSoft, non-tender
ExtremitiesNo leg swelling; calves soft and non-tender; left calf slightly smaller than the right, as before
SkinNo bruising or petechiae
NeurologicalFluent speech; strength full in all four limbs; steady gait; Timed Up and Go 9 seconds
PsychiatricWarm, engaged and direct

Problems

ProblemClinical statusVerificationCodeProvenance
Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review bookedresolvedconfirmed R29.818S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass.
Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pendingresolvedconfirmed D49.6S — Synthetic imaging diagnosis before surgery; superseded by the pathology.
Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain canceractiveconfirmed C71.1S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public.
Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndromeactiveconfirmed B91S — Documented childhood polio (D); the current absence of new symptoms is synthetic.
Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasoneresolvedconfirmed G93.6S — Synthetic finding on the first MRI.
Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroidsresolvedconfirmed R73.9S — Synthetic common effect of dexamethasone; resolved after the taper.
Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or betteractiveconfirmed D72.810S — Synthetic common effect of daily temozolomide with radiotherapy.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today118/72 mmHg
Depression screeningCompleted todayPHQ-2 score 1; PHQ-9 6 three weeks ago
Unhealthy alcohol use screeningCompleted todayNo alcohol since surgery
Tobacco useCompleted todayNever
Breast cancer screeningUp to dateMammogram every two years from 40 to 74; last screening mammogram about a year ago, normal; next to be decided with her when due
Cervical cancer screeningUp to dateCytology with HPV testing about two years ago, negative; next due in about three years
Colorectal cancer screeningUp to dateColonoscopy at 50, normal; next due at 60
Diabetes screeningUp to dateA1c 5.6% before steroids; glucose 91 mg/dL three weeks ago, off steroids
Lipid screeningDeclinedDeclined for now: not drawn today, by her choice, while she is on cancer treatment; to be revisited at the next preventive visit
HIV, hepatitis B and hepatitis C screeningUp to dateAll negative before temozolomide
Osteoporosis screeningNot indicatedPostmenopausal at 54; dexamethasone for under two months and no fracture, so her estimated fracture risk is below the threshold for bone density testing; to be reconsidered if steroids are needed again or she falls
Fall risk and mobilityCompleted todayNo falls; Timed Up and Go 9 seconds; home exercises and home safety measures in place
Lung cancer screeningNot indicatedNever smoker
Influenza, pneumococcal and zoster vaccinesCompleted todayInactivated influenza vaccine, PCV20 and recombinant zoster dose 1 given today; no live vaccines during chemotherapy
COVID-19 vaccine, this seasonDueAt her pharmacy, at least a few days apart from the next temozolomide cycle if she prefers
Dental and eye examinationsDueDental review and an eye examination advised this year

Immunizations given today: Influenza vaccine, inactivated, trivalent, preservative free, this season; Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026); TEMODAR (temozolomide) capsules, prescribing information (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Cervical Cancer: Screening (2018); Colorectal Cancer: Screening (2021); Osteoporosis to Prevent Fractures: Screening (2025); Adult Immunization Schedule by Medical Condition and Other Indication (2026)

Follow-up: Cycle 2 of temozolomide on day 29 with a blood count first. Neuro-oncology review and MRI after cycle 2. Second zoster dose in one to two months; COVID-19 vaccine this season. Next preventive visit in one year. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 20 minutes, with her consent, reviewing the advance directive she completed with the palliative care team last month. She wants treatment aimed at controlling the tumor for as long as it lets her live in a way she values, being at home and with the people she loves, and wants to be told plainly when that balance changes. Her named health care agent is recorded in the confidential part of the chart and is not named here. She asked that information about her health go only to the people she names. To be revisited at each MRI and if her illness changes. [S]